Literature DB >> 22739410

Lipid-lowering effect of berberine in human subjects and rats.

Yueshan Hu1, Erik A Ehli, Julie Kittelsrud, Patrick J Ronan, Karen Munger, Terry Downey, Krista Bohlen, Leah Callahan, Vicki Munson, Mike Jahnke, Lindsey L Marshall, Kelly Nelson, Patricia Huizenga, Ryan Hansen, Timothy J Soundy, Gareth E Davies.   

Abstract

Due to serious adverse effects and the limited effectiveness of currently available pharmacological therapies for obesity, many research efforts have focused on the development of drugs from natural products. Our previous studies demonstrated that berberine, an alkaloid originally isolated from traditional Chinese herbs, prevented fat accumulation in vitro and in vivo. In this pilot study, obese human subjects (Caucasian) were given 500 mg berberine orally three times a day for twelve weeks. The efficacy and safety of berberine treatment was determined by measurements of body weight, comprehensive metabolic panel, blood lipid and hormone levels, expression levels of inflammatory factors, complete blood count, and electrocardiograph. A Sprague-Dawley rat experiment was also performed to identify the anti-obesity effects of berberine treatment. The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects. But more interestingly, the treatment significantly reduced blood lipid levels (23% decrease of triglyceride and 12.2% decrease of cholesterol levels) in human subjects. The lipid-lowering effect of berberine treatment has also been replicated in the rat experiment (34.7% decrease of triglyceride and 9% decrease of cholesterol level). Cortisol, calcitriol, ACTH, TSH, FT4, and SHBG levels were not significantly changed following 12 weeks of berberine treatment. However, there was interestingly, an increase in calcitriol levels seen in all human subjects following berberine treatment (mean 59.5% increase, p=0.11). Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine. Tests of hematological, cardiovascular, liver, and kidney function following berberine treatment showed no detrimental side effects to this natural compound. Collectively, this study demonstrates that berberine is a potent lipid-lowering compound with a moderate weight loss effect, and may have a possible potential role in osteoporosis treatment/prevention.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739410     DOI: 10.1016/j.phymed.2012.05.009

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  34 in total

1.  Effect of anti-hyperlipidemia drugs on the alpha-tocopherol concentration and their potential for murine malaria infection.

Authors:  Aiko Kume; Maria Shirley Herbas; Mototada Shichiri; Noriko Ishida; Hiroshi Suzuki
Journal:  Parasitol Res       Date:  2015-09-11       Impact factor: 2.289

2.  The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters.

Authors:  Kai He; Xiaoli Ye; Hao Wu; YanZhi Wang; Zongyao Zou; Na Ning; Yinran Hu; Biao Chen; Xuedong Fang; Xuegang Li
Journal:  Lipids       Date:  2014-12-30       Impact factor: 1.880

Review 3.  Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.

Authors:  Navid Nourizadeh; Leila Vazifeh Mostaan; Ehsan Saburi; Seyed Isaac Hashemy
Journal:  Mol Biol Rep       Date:  2022-08-08       Impact factor: 2.742

4.  Berberine attenuates oxidative stress and hepatocytes apoptosis via protecting mitochondria in blunt snout bream Megalobrama amblycephala fed high-fat diets.

Authors:  Kang-Le Lu; Li-Na Wang; Ding-Dong Zhang; Wen-Bin Liu; Wei-Na Xu
Journal:  Fish Physiol Biochem       Date:  2016-08-06       Impact factor: 2.794

5.  Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.

Authors:  Jeffry Adiwidjaja; Alan V Boddy; Andrew J McLachlan
Journal:  Eur J Clin Pharmacol       Date:  2022-01-20       Impact factor: 2.953

Review 6.  Chinese herbal medicine on dyslipidemia: progress and perspective.

Authors:  Ming Guo; Yue Liu; Zhu-Ye Gao; Da-Zhuo Shi
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-13       Impact factor: 2.629

7.  Preclinical Pharmacokinetics and Pharmacodynamics of Coptidis Preparation in Combination with Lovastatin in High-Fat Diet-Induced Hyperlipidemic Rats.

Authors:  Wen-Ya Peng; Andy C Huang; Chin-Tsung Ting; Tung-Hu Tsai
Journal:  ACS Omega       Date:  2021-06-10

8.  Anti-hyperlipidemic effects and potential mechanisms of action of the caffeoylquinic acid-rich Pandanus tectorius fruit extract in hamsters fed a high fat-diet.

Authors:  Xiaopo Zhang; Chongming Wu; Haifeng Wu; Linghui Sheng; Yan Su; Xue Zhang; Hong Luan; Guibo Sun; Xiaobo Sun; Yu Tian; Yubin Ji; Peng Guo; Xudong Xu
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

9.  Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages.

Authors:  Weibin Zha; Guangji Wang; Weiren Xu; Xuyuan Liu; Yun Wang; Beth S Zha; Jian Shi; Qijin Zhao; Phillip M Gerk; Elaine Studer; Phillip B Hylemon; William M Pandak; Huiping Zhou
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

10.  Metformin and berberine prevent olanzapine-induced weight gain in rats.

Authors:  Yueshan Hu; Alan J Young; Erik A Ehli; Dustin Nowotny; Paige S Davies; Elizabeth A Droke; Timothy J Soundy; Gareth E Davies
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.